Piper Sandler analyst Joseph Catanzaro downgraded Turnstone Biologics (TSBX) to Neutral from Overweight with a price target of 40c, down from $3.75, after the company announced it is discontinuing all of its clinical studies evaluating TIDAL-01 and is exploring strategic alternatives. Piper removed all value for TIDAL-01 and downgraded the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSBX: